While most RET fusions involved HER2-negative breast cancers with variable estrogen receptor (ER) expression, presence of the NCOA4-RET fusion was also identified as a possible bypass pathway resistance mechanism to dual HER2-targeted therapy and aromatase inhibitor in a case of ER-positive, HER2-overexpressed breast cancer. The gene discussed is CYP19A1; the disease is breast cancer.